SOLSTICE NEUROSCIENCES, DREAMPHARMA IN LICENSING AGREEMENT FOR MYOBLOC

A A

Solstice Neurosciences Inc. has reached an Exclusive License Agreement with DreamPharma Corporation of Seoul, Korea, to evaluate and develop cosmetic and therapeutic uses of Myobloc (Botulinum Toxin Type B) Injectable Solution for a range of specialty biopharmaceutical products in Korean markets. The agreement includes the use of Myobloc in its injectable formulation as clostridium botulinum type B which was approved by the FDA in December 2000 and subsequently approved by the European Medicines Agency (EMEA) in January 2001.

BioSpectrum Asia (http://www.biospectrumasia.com/content/070706KOR1083.asp)